



**OFFICERS**

The Hon. John Edward Porter, Chair  
The Hon. Michael N. Castle, Vice Chair  
Mary Woolley, President  
Larry J. Shapiro, MD, Secretary  
Lucinda Maine, PhD, RPh, Treasurer

**BOARD MEMBERS**

Tenley E. Albright, MD  
Hortensia Amaro, PhD  
Georges C. Benjamin, MD  
Nancy Brown  
Susan Dentzer  
Victor J. Dzau, MD  
Joseph M. Fecko, MD  
Jay A. Gershen, DDS, PhD  
William N. Hait, MD, PhD  
Larry Hausner, MBA  
Mary J.C. Hendrix, PhD  
Martha N. Hill, PhD, RN  
Harry Johns  
Evan Jones  
Elizabeth Baker Keffer  
The Hon. Patrick J. Kennedy  
Debra R. Lappin, JD  
Alan I. Leshner, PhD  
James L. Madara, MD  
Mark McClellan, MD, PhD  
The Hon. Kweisi Mfume  
Herbert Pardes, MD  
Sudip S. Parikh, PhD  
E. Albert Reece, MD, PhD, MBA  
Amy Comstock Rick, JD  
John R. Seffrin, PhD  
Laing Rogers Sisto  
Gregory Sorensen, MD  
Jack T. Watters, MD  
Keith R. Yamamoto, PhD  
Elias A. Zerhouni, MD

May 15, 2014

The Honorable Harold Rogers  
Chairman  
Committee on Appropriations  
United States House of  
Representatives  
Washington, DC 20515

The Honorable Jack Kingston  
Chairman  
Subcommittee on Labor, Health and  
Human Services, Education, and  
Related Agencies  
Committee on Appropriations  
United States House of  
Representatives  
Washington, DC 20515

The Honorable Nita Lowey  
Ranking Member  
Committee on Appropriations  
United States House of  
Representatives  
Washington, DC 20515

The Honorable Rosa DeLauro  
Ranking Member  
Subcommittee on Labor, Health and  
Human Services, Education, and  
Related Agencies  
Committee on Appropriations  
United States House of  
Representatives  
Washington, DC 20515

Dear Chairman Rogers, Ranking Member Lowey, Chairman Kingston,  
Ranking Member DeLauro:

On behalf of Research!America and its more than 350 member organizations representing patients and other committed advocates for U.S medical progress, I write to thank you for taking on the enormously important and profoundly difficult task of allocating finite funding to a spectrum of American priorities.

As you consider how best to shepherd the strengths and values that have distinguished our nation since its birth in 1776, among them

- the belief in an unrivaled national defense;
- the commitment to individual freedom;
- the determination to drive human progress and foster the American Dream through ingenuity, entrepreneurialism, and community; and
- the unflagging commitment to positioning our nation as a leader, never a follower

we make a straightforward request: Do not let longer-term initiatives and proposals, as important as they are, divert from reasserting American priorities now.

1101 King Street  
Suite 520  
Alexandria, VA 22314-2960  
P 703.739.2577  
F 703.739.2372  
E [info@researchamerica.org](mailto:info@researchamerica.org)  
[www.researchamerica.org](http://www.researchamerica.org)

How does this relate to medical progress? Federal funding is lower now than it was in 2010 for the noncommercial medical research conducted at research universities and other research institutions around the country. Private sector medical innovation relies on this fundamental discovery, and medical innovation:

- arms our nation against increasingly sophisticated bioterrorism threats;
- protects our troops and empowers wounded warriors;
- is an engine for the export leadership needed to maintain our nation's global economic leadership;
- spurs U.S. business and job creation; and
- is the most effective weapon in our nation's arsenal for defeating deadly and disabling diseases that ultimately cause profound suffering for every single American – both patients and loved ones.

Medical progress does not serve one national priority, it serves many.

Despite their profound, longer-term importance, please do not let policy initiatives aimed at optimizing the efficiency of the research pipeline or identifying supplemental funding streams for medical research overshadow the immediate opportunity to accelerate medical progress through robust FY 15 allocations to the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Centers of Disease Control and Prevention (CDC), the Agency for Healthcare Research and Quality (AHRQ), and the National Science Foundation (NSF).

Patients cannot afford the wasted time implicit in withholding funding from the research pipeline while it is essentially “audited.” Accountability is critical, but so is medical progress. Demanding one should not preclude the other.

We need medical progress now, and fiscal year 2015 gives you a chance to reinvigorate it. Children are dying, deprived of their futures. Parents are dying, unable to participate in their child's lives. Wounded warriors are dying, faced with the impossible choice between unremitting PTSD and suicide. And that does not begin to catalogue the lost years and needless suffering that research can put a stop to...if Congress and the White House adhere to our nation's historic commitment to medical progress. The pause in advancing this American priority has gone on long enough. Please capitalize on the FY 15 appropriations process to save American lives.

Sincerely,

A handwritten signature in cursive script that reads "Ellie Dehoney". The signature is written in black ink and is positioned above the typed name and title.

Ellie Dehoney  
Vice President, Policy and Advocacy  
Research!America